LONDON (Reuters) - The National Institute for Health and Care Excellence (NICE) on Friday reversed an earlier decision to limit the use of Roche's Tarceva cancer pill on the state health service in a move the drugmaker said would help around 2,000 patients a year. New draft guidance from NICE now backs use of Tarceva for people with non-small-cell lung cancer that has progressed after chemotherapy in wider circumstances than originally suggested. ...
via Health News Headlines - Yahoo News http://ift.tt/1h9TzFm
via Health News Headlines - Yahoo News http://ift.tt/1h9TzFm
No comments:
Post a Comment